About Peroxisomal membrane protein PEX14
Peroxisomal membrane protein PEX14 (PEX14) is a protein
from Homo sapiens identified by UniProt accession
O75381, 377 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Peroxisomal membrane protein PEX14 |
| UniProt accession | O75381 |
| Gene | PEX14 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- peroxisome biogenesis disorder 13A (Zellweger) · score 0.73
- Zellweger syndrome · score 0.66
- peroxisome biogenesis disorder, complementation group K · score 0.48
- peroxisome biogenesis disorder · score 0.46
- neurodegenerative disease · score 0.45
- asthma · score 0.41
- breast carcinoma · score 0.38
- peroxisome biogenesis disorder, complementation group 7 · score 0.37
- peroxisome biogenesis disorder 11A (Zellweger) · score 0.37
- lysosomal storage disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75381-F1 | alphafold | PREDICTED | 67.86 | — |
Amino-acid sequence (377 residues)
MASSEQAEQP SQPSSTPGSE NVLPREPLIA TAVKFLQNSR VRQSPLATRR AFLKKKGLTD EEIDMAFQQS GTAADEPSSL GPATQVVPVQ PPHLISQPYS PAGSRWRDYG ALAIIMAGIA FGFHQLYKKY LLPLILGGRE DRKQLERMEA GLSELSGSVA QTVTQLQTTL ASVQELLIQQ QQKIQELAHE LAAAKATTST NWILESQNIN ELKSEINSLK GLLLNRRQFP PSPSAPKIPS WQIPVKSPSP SSPAAVNHHS SSDISPVSNE STSSSPGKEG HSPEGSTVTY HLLGPQEEGE GVVDVKGQVR MEVQGEEEKR EDKEDEEDEE DDDVSHVDEE DCLGVQREDR RGGDGQINEQ VEKLRRPEGA SNESERD
Explore Peroxisomal membrane protein PEX14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets